Contemporary issues surrounding folic acid fortification initiatives
Cardiovascular Benefits That Support Safe Combination Therapy Research published in major cardiology journals shows that semaglutide reduces the risk of major adverse cardiovascular events (MACE) by approximately 26% in people with type 2 diabetes and established heart disease
It also does have some lipogenic properties that are dependent on the status of insulin and glucose
Patients taking sulfonylureas, insulin, beta-blockers, diuretics, nonsteroidal anti-inflammatory drugs, statins, antidepressants, antipsychotics, or benzodiazepines should exercise caution when taking semaglutide as it may interact with these medications
Prospective cohort studies have reported that vitamin C intake from supplements (161, 162) or vitamin E intake from food and supplements (161) was associated with some protection against cognitive decline
Dose Escalation GLP-1 medications are typically introduced at a low dose and increased gradually